InflaRx (IFRX) Cash & Equivalents Growth (1y) (2017 - 2026)
InflaRx (IFRX) Cash & Equivalents Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 34.71% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 84.98% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 53.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.35% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -57.58% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 28.50% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.71% |
| Dec 31, 2025 | -5.15% |
| Sep 30, 2025 | -73.81% |
| Jun 30, 2025 | -28.63% |
| Mar 31, 2025 | 82.39% |
| Dec 31, 2024 | 43.13% |
| Sep 30, 2024 | 21.86% |
| Jun 30, 2024 | -2.95% |
| Mar 31, 2024 | 1,111.47% |
| Dec 31, 2023 | -17.22% |
| Sep 30, 2023 | 30.29% |
| Jun 30, 2023 | 29.19% |
| Mar 31, 2023 | -95.00% |
| Dec 31, 2022 | -44.74% |
| Sep 30, 2022 | -78.03% |
| Jun 30, 2022 | -81.12% |
| Mar 31, 2022 | -52.62% |
| Dec 31, 2021 | -3.01% |
| Sep 30, 2021 | 57.56% |
| Jun 30, 2021 | 117.36% |